Clinical Trials

Inclusion Criteria - Patient:

• Hospitalized patients (age ≥ 18 years) with high-risk AML defined as:
  • Patients with new diagnosis ≥ 60 years of age;
  • An antecedent hematologic disorder;
  • Therapy related-disease;
  • Relapsed or primary refractory AML.
• Receiving treatment with either:
  • intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen requiring prolonged hospitalization; or
  • hypomethylating agents +/- additional agents or modification of this regimen on a clinical trial.

Inclusion Criteria - Caregiver:

• Adult (≥ 18 years) relative or friend of a participating patient who the patient identifies as living with or has in-person contact with them at least twice per week.

Exclusion Criteria - Patient:

• Patients with a diagnosis of acute promyelocytic leukemia (APML).
• Patients with AML receiving supportive care alone.
• Patients with psychiatric or cognitive conditions which the treating clinicians believe prohibits informed consent or compliance with study procedures.
• Patients seen by a palliative care clinician [MD or APP] during two hospitalizations in the six months prior to enrollment.

Eligibility last updated 11/27/23. Questions regarding updates should be directed to the study team contact.